Nextnrg, Inc. (NXXT) · Oct 27, 2026 · Delisting
Nasdaq MVLS deficiency — MVLS below $35 million; 180-day cure period ends April 19, 2027
NextNRG’s Nasdaq delisting case now includes a new market-value breach, adding pressure while its appeal decision remains pending.
NextNRG is trying to commercialize an AI-driven Smart Controller for microgrids while building an energy-services and licensing business.
The listing problem is now broader, not merely unresolved. Nasdaq says NextNRG’s market value of listed securities stayed below the $35 million threshold for 30 consecutive business days. The company also does not satisfy the $2.5 million stockholders’ equity or $500,000 net-income alternatives, leaving few obvious compliance routes.
| Listing test or deadline | Filing detail |
|---|---|
| MVLS requirement | $35 million |
| Stockholders’ equity alternative | $2.5 million |
| Net-income alternative | $500,000 |
| Compliance period | 180 calendar days |
| Cure deadline | April 19, 2027 |
| Required MVLS recovery | At least $35 million for 10 consecutive business days |
The notice does not immediately halt trading, but it raises the stakes for the pending appeal. 〔0〕 NextNRG was already appealing Nasdaq’s September 15 delisting determination tied to the $1 minimum bid-price rule after its 1-for-10 reverse split failed to resolve the issue. This new deficiency gives the Nasdaq Panel an additional basis to weigh against continued listing, rather than providing a clean administrative fix.
The company has time, but not a demonstrated recovery. The filing provides until April 19, 2027 to restore either market value or qualifying equity, yet it offers no completed financing, equity level, or operating milestone showing that compliance is within reach. The hearing occurred on October 22, and the final written decision remains pending. 〔1〕
Bottom line: This is a meaningful negative addition to an already-known delisting fight. The company retains a cure window, but the filing confirms that both market value and balance-sheet alternatives are currently deficient while Nasdaq’s appeal decision is still outstanding.
Nasdaq Panel decision on continued listing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!